Diabetes sales represent 66% of the total sales for metabolic disorders and will continue to be the major revenue generator in this therapeutic area.

Currently, eight out of 10 top-selling drugs in the metabolic disorders space are diabetes drugs, but these drugs will not be the main drivers of the growth over the next six years, as they have reached the peak of their sales. The top five drivers of the metabolic market growth will include more recently launched or soon-to-launch diabetes therapies (Eli Lilly’s Trulicity [dulaglutide] and Novo Nordisk’s Tresiba [insulin degludec] and semaglutide), as well as cholesterol-lowering/dyslipidemia drugs (Amgen’s Repatha [evolocumab] and Sanofi/Regeneron’s Praluent [alirocumab]). If we look at the top 10 contenders, diabetes drugs will constitute eight out of 10 top drivers in the metabolic space.

The diabetes market has long been a lucrative space for drug developers, as this disease is highly prevalent, with numbers continuously increasing and reaching 10% of the population in some parts of the world. In addition, many major pharmaceutical companies have been investing in this area, leading to a high number of marketed branded therapies as well as a rich pipeline. Despite the fact that the late-stage pipeline for diabetes is filled with ‘me-too’ therapies, many of these drugs are among the top 10 drivers of the metabolic disorders market.

Apart from drugs for diabetes and dyslipidemia, which occupy the top 10 places, the top 15 drivers of the metabolic market growth also include therapies for osteoporosis (Amgen’s Prolia [denosumab]) and hyperkalemia (AstraZeneca’s Lokelma [sodium zirconium cyclosilicate]).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.